TY - JOUR
T1 - A nationwide survey concerning the mortality and risk of progressing severity due to arterial and venous thromboembolism in inflammatory bowel disease in Japan
AU - Ando, Katsuyoshi
AU - Fujiya, Mikihiro
AU - Watanabe, Kenji
AU - Hiraoka, Sakiko
AU - Shiga, Hisashi
AU - Tanaka, Shinji
AU - Iijima, Hideki
AU - Mizushima, Tsunekazu
AU - Kobayashi, Taku
AU - Nagahori, Masakazu
AU - Ikeuchi, Hiroki
AU - Kato, Shingo
AU - Torisu, Takehiro
AU - Kobayashi, Kiyonori
AU - Higashiyama, Masaaki
AU - Fukui, Toshiro
AU - Kagaya, Takashi
AU - Esaki, Motohiro
AU - Yanai, Shunichi
AU - Abukawa, Daiki
AU - Naganuma, Makoto
AU - Motoya, Satoshi
AU - Saruta, Masayuki
AU - Bamba, Shigeki
AU - Sasaki, Makoto
AU - Uchiyama, Kazuhiko
AU - Fukuda, Katsuyuki
AU - Suzuki, Hideo
AU - Nakase, Hiroshi
AU - Shimizu, Toshiaki
AU - Iizuka, Masahiro
AU - Watanabe, Mamoru
AU - Suzuki, Yasuo
AU - Hisamatsu, Tadakazu
N1 - Funding Information:
The author(s) disclose receipt of the following financial support for the research, authorship, and/or publication of this article: This paper was supported by Intractable Disease Health and Labour Sciences Research Grants from the Ministry of Health, Labour and Welfare.
Funding Information:
M.F. received lecture fees from Nippon Kayaku Co., Ltd., Janssen Pharmaceutical K.K., Takeda Pharmaceutical Co. Ltd., AbbVie GK., JIMRO Co. Ltd., AYUMI Pharmaceutical Corporation, and research grant from Nippon Kayaku Co. Ltd., Takeda Pharmaceutical Co. Ltd., Janssen Pharmaceutical K.K.,AbbVie GK., EA pharma Co. Ltd., AYUMI Parmaceutical Industries Co. Ltd. K.W. received (1) lecture fees from Abbvie GK., EA Pharma Co.,Ltd., Kissei Pharmaceutical Co., Ltd., Pfizer Lnc.,Kyorin Pharmaceutical Co.,Ltd., Mitsubishi Tanabe Pharma Corporation, Janssen Pharmaceutical K.K, Takeda Pharmaceutical Co.,Ltd., Zeria Pharmaceutical Co.,Ltd., Mochida Pharmaceutical Co.,Ltd., (2) research and scholarship grants from EA Pharma Co.,Ltd., Takeda Pharmaceutical Co.,Ltd., EP-CRSU Co. Ltd., and (3) endowed chair from AbbVie GK., EA pharma Co. Ltd., Mitsubishi Tanabe Pharma Co., Zeria Pharmaceutical Co.,Ltd., Asahi Kasei Medical Co.,Ltd., and Mochida Pharmaceutical Co.,Ltd. S.H. received lecture fees from Janssenn Pharaceutical K.K., Mitsubishi Tanabe Pharma Co. T.M. received endowed chair from Kinshukai Medical Corporation. T.K. received lecture fees AbbVie GK., Alfresa Pharma Co., Janssen Pharmaceutical K.K., Takeda Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Co., Pfizer Lnc., Mochida Pharmaceutical Co.,Ltd., and research grants from Nippon Kayaku Co., Ltd. and EA pharma Co. Ltd., and scholarship grants from Otsuka Holdings, JIMRO Co. Ltd., EA pharma Co. Ltd., AbbVie GK and Zeria Pharmaceutical Co.,Ltd. and Pfizer Lnc. M.N. received lecture fees from Takeda Pharmaceutical Co. Ltd., and research grant from Hitachi Ltd. S.K. Received lecture fees from AbbVie GK., Janssen Pharmaceutical K.K. and Mitsubishi Tanabe Pharma Co., and scholarship grants from AbbVie GK. and EA pharma Co. Ltd. T.T received research grants from Mitsubishi Tanabe Pharma Corporation, EA Pharma Co., AbbVie GK., Zeria Pharmaceutical Co., Ltd. M.N. received lecture fees from Takeda Pharmaceutical Co. Ltd., AbbVie GK., Mitsubishi Tanabe Pharma Co. and Pfizer Inc., and research grant from Mochida Pharmaceutical Co. Ltd., and scholarship grants from EA Pharma Co., AbbVie GK. and Mitsubishi Tanabe Pharma Co. H.N. received lecture fees from AbbVie GK., Kissei Pharmaceutical Co. Ltd., Kyorin Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Co., Janssen Pharmaceutical K.K., Takeda Pharmaceutical Co. Ltd., Pfizer Inc., Celgene Co. and EA pharma Co. Ltd., and research grants from HOYA Group Pentax Medical, Mitsubishi Tanabe Pharma Co., Pfizer Lnc., AbbVie GK and Mochida Pharmaceutical Co., and scholarship grants from AbbVie GK, Mitsubishi Tanabe Pharma Co., Takeda Pharmaceutical Co. Ltd., Nippon Kayaku Co. Ktd., Otsuka Pharmaceutical Co. Ltd. and EA Pharma Co. Ltd. T.H. received lecture fees from Mitsubishi Tanabe Pharma Corporation, AbbVie GK, EA pharma Co. Ltd., Kyorin Pharmaceutical Co. Ltd., JIMRO Co., Janssen Pharmaceutical K.K., Mochida Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co. Ltd., consulting fees from EA pharma Co. Ltd., AbbVie GK, Celgene K.K., Janssen Pharmaceutical K.K., Pfizer Inc., Nichi-Iko Pharmaceutical Co., Ltd. and research grant from Alfresa Pharma Co. Ltd., EA pharma Co. Ltd., scholarship grants from Mitsubishi Tanabe Pharma Corporation, EA pharma Co. Ltd.AbbVie GK, JIMRO Co. Ltd., Zeria Pharmaceutical Co. Ltd., Daiichi-Sankyo, Kyorin Pharmaceutical Co. Ltd., Nippon Kayaku Co. Ltd., Takeda Pharmaceutical Co. Ltd., Pfizer Inc., Mochida Pharmaceutical Co., Ltd.
Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - Background: The mortality and risk factors of severe disease and death due to arterial and venous thromboembolism (ATE and VTE, respectively) in patients with inflammatory bowel disease (IBD) remain unclear, especially in Asia. Aims: This study aimed to reveal the mortality and risk factors of TE in IBD patients in Japan. Methods: In the primary surveillance, responses to questionnaires regarding the number of cases of severe TE and TE-associated death in IBD patients in a span of over the past 10 years were obtained from 32 institutions in Japan. In the secondary surveillance, detailed data about IBD patients with TE were collected. The characteristics, laboratory data, therapy status, and situation at the time of TE development were retrospectively collected, and the data were compared between the patients with and without severe TE and TE-associated death. Results: The incidence of TE was 1.89% among 31,940 IBD patients. The frequencies of severe TE and TE-associated mortality were 10.7% and 1.0% among the total IBD and TE with IBD patients, respectively. The only risk factor for severe ATE and ATE-associated death was ischemic heart disease. The independent risk factors for severe VTE and VTE-associated death were age (≤ 45 years old), the site of VTE, and disease severity, with anti-TNF therapy as a potential negative risk factor. Patients with severe VTE had a high risk of developing persistent VTE and sequelae. Conclusion: Unlike ATE, the incidence of VTE was comparable in Asian and Western countries. Therapeutic and prophylactic strategies for managing IBD-associated TE in Asia are urgently needed.
AB - Background: The mortality and risk factors of severe disease and death due to arterial and venous thromboembolism (ATE and VTE, respectively) in patients with inflammatory bowel disease (IBD) remain unclear, especially in Asia. Aims: This study aimed to reveal the mortality and risk factors of TE in IBD patients in Japan. Methods: In the primary surveillance, responses to questionnaires regarding the number of cases of severe TE and TE-associated death in IBD patients in a span of over the past 10 years were obtained from 32 institutions in Japan. In the secondary surveillance, detailed data about IBD patients with TE were collected. The characteristics, laboratory data, therapy status, and situation at the time of TE development were retrospectively collected, and the data were compared between the patients with and without severe TE and TE-associated death. Results: The incidence of TE was 1.89% among 31,940 IBD patients. The frequencies of severe TE and TE-associated mortality were 10.7% and 1.0% among the total IBD and TE with IBD patients, respectively. The only risk factor for severe ATE and ATE-associated death was ischemic heart disease. The independent risk factors for severe VTE and VTE-associated death were age (≤ 45 years old), the site of VTE, and disease severity, with anti-TNF therapy as a potential negative risk factor. Patients with severe VTE had a high risk of developing persistent VTE and sequelae. Conclusion: Unlike ATE, the incidence of VTE was comparable in Asian and Western countries. Therapeutic and prophylactic strategies for managing IBD-associated TE in Asia are urgently needed.
KW - Arterial thromboembolism
KW - Inflammatory bowel disease
KW - Mortality
KW - Severity
KW - Venous thromboembolism
UR - http://www.scopus.com/inward/record.url?scp=85116484861&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85116484861&partnerID=8YFLogxK
U2 - 10.1007/s00535-021-01829-5
DO - 10.1007/s00535-021-01829-5
M3 - Article
C2 - 34611740
AN - SCOPUS:85116484861
SN - 0944-1174
VL - 56
SP - 1062
EP - 1079
JO - Journal of Gastroenterology
JF - Journal of Gastroenterology
IS - 12
ER -